Table 3.
All | Anti-TB | No anti-TB | OR | p | |
---|---|---|---|---|---|
All |
70 |
22 (31)*† |
48 (68) |
|
|
Death before 2 weeks |
9 (13) |
1 (4) |
8 (17) |
0.25 (0.03–2.0) |
0.25 |
Any death |
18 (26) |
2 (9) |
16 (33) |
0.2 (0.04–0.96) |
0.04 |
Pediatric |
23 |
7 (30) |
16 (69) |
|
|
Death before 2 weeks |
2 (9) |
1 (14) |
1 (6) |
2.5 (0.13–46.8) |
0.53 |
Any death |
4 (17) |
1 (14) |
3 (19) |
0.72 (0.06–8.5) |
0.66 |
Adult |
47 |
15 (32) |
32 (68) |
|
|
Death before 2 weeks |
7 (15) |
0 |
7 (22) |
undefined |
0.08 |
Any death |
14 (30) |
1 (7) |
13 (41) |
0.10 (0.01–0.89) |
0.02 |
HIV-infected |
34 |
10 (29) |
24 (71) |
|
|
Death before 2 weeks |
5 (15) |
0 |
5 (21) |
undefined |
0.29 |
Any death |
9 (26) |
0 |
9 (38) |
undefined |
0.01 |
Smear-negative |
59 |
13 (22) |
46 (78) |
|
|
Death before 2 weeks |
7 (12) |
0 |
7 (15) |
undefined |
0.33 |
Any death |
15 (25) |
1 (8) |
14 (30) |
0.19 (0.02–1.6) |
0.15 |
Standard arm |
37 |
12 (32) |
25 (68) |
|
|
Death before 2 weeks |
4 (11) |
0 |
4 (19) |
undefined |
0.19 |
Any death |
9 (24) |
1 (8) |
8 (32) |
0.19 (0.05–1.5) |
0.12 |
Intensified arm |
33 |
10 (30) |
23 (70) |
|
|
Death before 2 weeks |
5 (15) |
1 (10) |
4 (17) |
0.53 (0.20–1.4) |
0.29 |
Any death | 9 (27) | 1 (10) | 8 (35) | 0.20 (0.00–1.4) | 0.15 |
*An additional 2 patients were prescribed anti–TB but died before initiating therapy.
†Percentages refer to proportion of total in each category.
p–values in bold are statistically significant at a level of p<0.05.